Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01326702
Recruitment Status : Completed
First Posted : March 31, 2011
Last Update Posted : October 15, 2015
Information provided by (Responsible Party):
National Cancer Institute (NCI)